Chronic periodontitis (CP) is an inflammatory disease of the tooth supporting structures caused by colonization of the periodontal tissues with specific oral pathogens representing itself clinically as attachment loss attributable to periodontal ligament breakdown and loss of the adjacent supporting bone in certain susceptible individuals. Elimination of etiological factors should be one of the prime goals in the successful treatment and in that case prevention of recurrence of any disease under consideration. Satranidazole is an antiprotozoal & antibacterial drug belonging to nitroimidazole group of drugs. Satranidazole (CG-10213-Go), 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone is a novel nitroimidazole which differs from other 5-nitroimidazoles such as metronidazole, ornidazole, and tinidazole in that the 2C of the imidazole ring is connected via a nitrogen to a substituted imidazolidinone moiety.The systemic use of SZ, when used as an adjunct to non-surgical periodontal therapy in subjects with periodontitis, achieves significantly better clinical and microbiological results than scaling and root planing alone.